C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Cons

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors?

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sect

At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate,

At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate,

I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CEL

C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about

Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Out

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a cli

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a cli

Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed comp

US stocks mixed, Nasdaq up 200 points. Dow down 0.43%, Nasdaq up 0.79%, S&P 500 up 0.27%. Commun

Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeu

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.2 per share versus the Zacks Conse

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.20) per share which beat the analyst

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a cli

C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in miles

C4 Therapeutics said on Thursday it has entered into a deal ​focused on research and development of

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to a

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Th

C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) was the target of a large increase in short i

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to thei

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to a

Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combinatio

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcrip

C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tig

WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a c

Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raise

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst

Brookline Capital analyst Leah Rush maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidom

 Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100

Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lower

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.44) per share which missed the analys

Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and r

Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics (NASDAQ:CCCC) with a Overw